--- title: "Teladoc | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 613.85 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/284691188.md" datetime: "2026-04-30T04:12:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284691188.md) - [en](https://longbridge.com/en/news/284691188.md) - [zh-HK](https://longbridge.com/zh-HK/news/284691188.md) --- # Teladoc | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 613.85 M Revenue: As of FY2026 Q1, the actual value is USD 613.85 M, beating the estimate of USD 610.72 M. EPS: As of FY2026 Q1, the actual value is USD -0.36, missing the estimate of USD -0.341. EBIT: As of FY2026 Q1, the actual value is USD -62.89 M. #### First Quarter 2026 Financial Highlights Teladoc Health, Inc. reported a net loss of -$63.8 million for the first quarter of 2026, or -$0.36 per share. Adjusted EBITDA for the quarter was $58.2 million, which remained essentially flat year-over-year . #### Segment Performance ##### Integrated Care Segment Adjusted EBITDA for the Integrated Care segment was $56.277 million, marking a 12% increase from $50.379 million in the first quarter of 2025. The Adjusted EBITDA margin for Integrated Care stood at 14.2% . ##### BetterHelp Segment Adjusted EBITDA for the BetterHelp segment was $1.892 million, representing a 75% decrease from $7.714 million in the first quarter of 2025. The Adjusted EBITDA margin for BetterHelp was 0.9% . Within BetterHelp, Consumer and Other revenue was $205.463 million, a 14% decrease from $239.901 million in Q1 2025, while Insurance Covered Services generated $12.937 million . #### Revenue by Type and Geography Access Fees revenue decreased by 8% year-over-year to $484.655 million from $525.736 million. Other revenue increased by 25% to $129.190 million from $103.633 million . U.S. revenue decreased by 6% to $491.505 million from $524.970 million, while International revenue increased by 17% to $122.340 million from $104.399 million . #### Operational Costs (First Quarter 2026 vs. First Quarter 2025) Total costs and expenses were $675.613 million, down from $749.980 million. Cost of revenue was $197.526 million, a slight increase from $196.829 million . Advertising and marketing expenses decreased to $151.527 million from $168.185 million, and technology and development costs decreased to $67.865 million from $69.958 million . General and administrative expenses also decreased to $102.093 million from $112.774 million, while sales expenses increased to $51.276 million from $48.693 million . Restructuring costs increased to $11.975 million from $4.347 million, and amortization of intangible assets was $89.826 million, up from $84.304 million . Goodwill impairment was $0 in Q1 2026, compared to $59.138 million in Q1 2025 . Loss from operations improved to -$61.768 million from -$120.611 million in the prior year . #### Cash Flow Cash flow from operations was $9.5 million in the first quarter of 2026, down from $15.9 million in the first quarter of 2025. Capital expenditures and capitalized software development costs (Capex) totaled $35.8 million, compared to $31.6 million in the prior year period . Free cash flow was an outflow of -$26.3 million, compared to an outflow of -$15.7 million in the first quarter of 2025 . #### Other Operational Metrics Total Visits were 4.4 million, a 2% decrease year-over-year. U.S. Integrated Care Members stood at 101.2 million, a 1% decrease from 102.5 million . Chronic Care Program Enrollment increased by 4% to 1.197 million from 1.151 million, and Average Monthly Revenue Per U.S. Integrated Care Member was $1.30, a 2% increase from $1.27 . BetterHelp Paying Users averaged 0.361 million, a 9% decrease from 0.397 million . #### Financial Outlook Teladoc Health, Inc. reaffirmed the midpoint of its full-year 2026 financial outlook, projecting revenue between $2,481 million and $2,576 million, Adjusted EBITDA between $267 million and $306 million, and Free Cash Flow between $130 million and $170 million. The company anticipates a full-year net loss per share between -$1.05 and -$0.75, with U.S. Integrated Care Members expected to range from 97 million to 100 million . For the second quarter of 2026, Teladoc Health, Inc. projects revenue between $597 million and $626 million, Adjusted EBITDA between $55 million and $67 million, and net loss per share between -$0.30 and -$0.20 . ### Related Stocks - [TDOC.US](https://longbridge.com/en/quote/TDOC.US.md) ## Related News & Research - [Teladoc Health Target of Unusually Large Options Trading (NYSE:TDOC)](https://longbridge.com/en/news/286944473.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)